Q1 2023 Results
Company overview
Financial review
Innovation: Pipeline overview
Financial performance
Cardiovascular
Immunology
niseovkitug - TGF-beta 1 inhibitor
NCT04935359 daNIS-2 (CNIS793B12301)
Indication
Phase
1L metastatic pancreatic ductal Adenocarcinoma
Phase 3
Patients
501
Primary
Outcome
Measures
Arms
Intervention
Conclusions
Safety run-in part: Percentage of participants with dose limiting toxicities
(DLTs) during the first cycle (4 weeks) of treatment
Randomized part: Overall survival (OS)
Safety run-in part: NIS793+gemcitabine+nab-paclitaxel
Randomized portion of the study:
Arm 1: NIS793+gemcitabine+nab-paclitaxel
Arm 2: placebo+gemcitabine+nab-paclitaxel
Patients with Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC), first
line treatment
Primary: 2024
Target
Patients
Readout
Milestone(s)
Publication
NA
75 Investor Relations | Q1 2023 Results
Appendix
Innovation: Clinical trials
Neuroscience
Oncology
References
Abbreviations
Other
NOVARTIS | Reimagining MedicineView entire presentation